Back to Search Start Over

Conjunctival Lymphoma.

Authors :
McGrath LA
Ryan DA
Warrier SK
Coupland SE
Glasson WJ
Source :
Eye (London, England) [Eye (Lond)] 2023 Apr; Vol. 37 (5), pp. 837-848. Date of Electronic Publication: 2022 Jul 26.
Publication Year :
2023

Abstract

Lymphoma of the conjunctiva is an ocular malignancy derived from clonal proliferation of lymphocytes. The majority of conjunctival lymphoma is extranodal marginal zone B-Cell lymphoma (EMZL), however diffuse large B-cell (DLBCL), follicular (FL), mantle cell (MCL) and T- cell subtypes are also seen. Clinical manifestations are non-specific, but include unilateral or bilateral painless salmon-pink conjunctival lesions. Approaches to treatment have centered around local immunomodulation, often with Interferon-α2b or Rituximab (anti-CD20 monoclonal antibody) with or without radiation. Although conjunctival lymphoma is generally considered an indolent disease, recent advances in next-generation sequencing have improved clinicians' ability to predict future recurrence or systemic disease through assessment of cytogenic and molecular features. In this paper, we review the classification, clinical features, diagnostic techniques, and emerging strategies for management and prognostication of conjunctival lymphomas.<br /> (© 2022. The Author(s).)

Details

Language :
English
ISSN :
1476-5454
Volume :
37
Issue :
5
Database :
MEDLINE
Journal :
Eye (London, England)
Publication Type :
Academic Journal
Accession number :
35882984
Full Text :
https://doi.org/10.1038/s41433-022-02176-2